The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2019 | Undetectable MRD after obinutuzumab plus venetoclax in CLL
Barbara Eichhorst, MD, University of Cologne, Cologne, Germany, discusses the prospective analysis of the randomized CLL14 trial (NCT02242942). This multinational, open-label, phase III study was designed to compare the efficacy and safety of a combined regimen of obinutuzumab plus venetoclax versus obinutuzumab and chlorambucil in patients with chronic lymphocytic leukemia (CLL) and coexisting medical conditions. Dr Eichhorst highlights the MRD data; in this study, MRD was analyzed by conventional PCR and additionally by next-generation sequencing (NGS). Findings confirmed the prognostic value of MRD assessment at the end of treatment for this combined regimen of obinutuzumab plus venetoclax. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.
